Skip to main content

Table 2 Vascular assessments before and after rosuvastatin treatment in SSc patients

From: Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis - a prospective case-series study

Parameter

Pre-treatment mean (S.D.)

Post-treatment mean (S.D.)

P valuea

FMD (%)

2.3 (3.3)

5.7 (3.9)

0.0002

Right ccIMT (mm)

0.675 (0.144)

0.681 (0.142)

ns (0.38)

Left ccIMT (mm)

0.717 (0.172)

0.701 (0.165)

ns (0.3)

Carotid-femoral PWV (m/s)

8.7 (2.6)

8.1 (1.9)

ns (0.1)

Aorto-femoral PWV (m/s)

8.8 (2.2)

8.3 (2.1)

ns (0.15)

Right Ankle-Brachial Index

1.1 (0.16)

1.1 (0.27)

ns (0.4)

Left Ankle-Brachial Index

1.1 (0.14)

1.1 (0.19)

ns (0.4)

Laser Doppler acceleration slope (U/s)

14.6 (14.8)

10.0 (10.3)

ns (0.08)

Laser Doppler deceleration slope (U/s)

-1.13 (0.92)

-0.64 (1.09)

0.021

  1. aSignificant differences are indicated in bold. ccIMT, common carotid intima-media thickness; FMD, flow-mediated vasodilation; ns, non significant; PWV, pulse wave velocity; SSc, systemic sclerosis.